Regeneron Stock Today

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;padding-top: 25px;;'>RP</div>
Regeneron Pharmaceuticals is selling for 620.86 as of the 12th of July 2020. This is -3.09 percent decrease since the beginning of the trading day. The stock's open price was 640.63. Regeneron Pharmaceuticals has a very small chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 30 days. Equity ratings for Regeneron Pharmaceuticals are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 13th of April 2020 and ending today, the 12th of July 2020. Click here to learn more.
Analyze Filter   Report: 5th of August 2020

8 100 

Regeneron Pharmaceuticals Profile

The upcoming quarterly report is expected on the 5th of August 2020. Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on BATS Exchange. It employs 8030 people. more on Regeneron Pharmaceuticals
Legal NameRegeneron Pharmaceuticals
President CEO, DirectorLeonard SchleiferView All
Thematic Classification
Currently Active Investing Idea
  Cancer Fighters
View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Regeneron Pharmaceuticals. The Regeneron consensus assessment is calculated by taking the average estimates from all of the analysts covering Regeneron Pharmaceuticals
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Regeneron Pharmaceuticals financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 7 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares99.5 M109.2 M
Significantly Down
Slightly volatile
Weighted Average Shares Diluted106.2 M114.6 M
Significantly Down
Slightly volatile
Net Cash Flow from Operations2.6 B2.4 B
Significantly Up
Slightly volatile
Total Assets16 B14.8 B
Significantly Up
Slightly volatile
Total LiabilitiesB3.7 B
Significantly Up
Slightly volatile
Current Assets8.3 B7.7 B
Significantly Up
Slightly volatile
Current Liabilities2.3 B2.1 B
Significantly Up
Slightly volatile
Total Debt349.8 M431 M
Significantly Down
Return on Average Assets13.6115.9444
Fairly Down
Slightly volatile
Gross Margin10290.0526
Moderately Up
Asset Turnover0.610.5926
Fairly Up
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Regeneron Pharmaceuticals available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Financial Strength
Regeneron Pharmaceuticals financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Regeneron Pharmaceuticals success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
  Operating Cash Flow
Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 8,030 people. The company currently falls under 'Large-Cap' category with current market capitalization of 63.7 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regeneron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Regeneron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Regeneron Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 100.75 M outstanding shares of which 2.47 M shares are at this time shorted by private and institutional investors with about 1.23 trading days to cover. REGENERON PHARMAC currently holds about 4 B in cash with 2.23 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 35.95.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Regeneron Stock Price Odds Analysis

Odds Down 620.86HorizonTargetOdds Up 620.86
87.00%30 days
Based on a normal probability distribution, the odds of Regeneron Pharmaceuticals to move above the current price in 30 days from now is about 12.89 (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Regeneron Stock Institutional Holders

InstituionSecurity TypeTotal SharesValue
Nelson Van Denburg Campbell Wealth Management Group LlcCommon Shares2.1 K1.3 M
Fmr LlcCommon Shares8.5 M4.1 B
Susquehanna International Group LlpCall Options929.5 K453.9 M
View Regeneron Pharmaceuticals Diagnostics

Regeneron Pharmaceuticals Income Statement Over Time

Regeneron Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Regeneron's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Regeneron Pharmaceuticals revenue and expense. Regeneron Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period. Regeneron Pharmaceuticals Interest Expense is quite stable at the moment as compared to the past year. The company's current value of Interest Expense is estimated at about 6.65 Million. Net Income is projected to rise to about 2.3 B this year, although the value of Weighted Average Shares will most likely fall to about 99.5 M. View More Fundamentals

Regeneron Stock Against Markets

Did you try this?

Run Portfolio Center Now


Portfolio Center

All portfolio management and optimization tools to improve performance of your portfolios
All  Next Launch Module

Regeneron Pharmaceuticals Upcoming and Recent Events

Regeneron Pharmaceuticals Company Earnings Announcements Dates

Upcoming Quarterly Report5th of August 2020
Next Earnings Report3rd of November 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End4th of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Regeneron Pharmaceuticals Corporate Directors

Charles Baker Independent Director
Joseph Goldstein Independent Director
Anthony Coles Independent Director
Additionally, take a look at Your Equity Center. Please also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page